Factors Associated With Normal Flow (TIMI 3) After Thrombolysis With Streptokinase in ST-Elevation Myocardial Infarction: A Prospective Observational Study

Karthik Raghuram 1, Surendran Deepanjali 1, Ajith Ananthakrishna Pillai 2

1. Medicine, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, IND 2. Cardiology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, IND

Corresponding author: Surendran Deepanjali, deepanjalis@gmail.com

Abstract

Background

Thrombolysis with streptokinase (STK) is the most widely used reperfusion strategy for ST elevation myocardial infarction (STEMI) in India. Achieving full reperfusion as evidenced by thrombolysis in myocardial infarction (TIMI) flow grade 3 in coronary angiography (CAG) is associated with better outcomes. Recent studies show that hematological indices like neutrophil-lymphocyte ratio (NLR) and mean platelet volume (MPV) estimated before thrombolysis could predict TIMI 3 flow. We studied clinical, electrocardiographic and hematological parameters associated with TIMI 3 flow after thrombolysis with STK.

Methods

We prospectively studied 201 adult patients with STEMI presenting within 12 hours of onset of chest pain. Before thrombolysis, blood sample was collected for estimating NLR and MPV. Timing of CAG after thrombolysis was decided by consultant cardiologists. Patients were followed up for one month after discharge.

Results

Of 201 patients, 162 (81%) had relief of chest pain and 131 (65%) had ST segment recovery of ≥50% at 90 minutes after thrombolysis. CAG was performed within median (IQR) of four (3-5) days after thrombolysis. TIMI 3 flow was observed in 112 (56%) patients. NLR and MPV had no significant association with TIMI 3 flow. In multivariable analysis, ST-segment recovery of ≥50% at 90 minutes was associated with TIMI 3 flow (adjusted OR 3.47, 95% CI: 1.84-6.53, P < 0.001). Of 198 patients followed up for one month after discharge, 13 (6.5%) died.

Conclusions

In patients with STEMI, ST-segment recovery of ≥50% at 90 minutes after thrombolysis with STK predicted TIMI 3 flow independently. NLR and MPV values were not predictive of TIMI 3 flow.

Introduction

Primary percutaneous coronary intervention (PPCI) is accepted as the most preferred reperfusion strategy for ST elevation myocardial infarction (STEMI). However, in many low and middle income countries (LMICs) like India, thrombolysis with streptokinase (STK) remains the most commonly used reperfusion strategy [1]. The primary aim of thrombolysis is to achieve rapid and complete patency of the infarct-related artery (IRA). Existing evidence suggests that full reperfusion as designated by thrombolysis in myocardial infarction (TIMI) flow grade 3 in coronary angiography (CAG) is associated with better myocardial salvage and decreased mortality [2]. Previous studies show that factors such as type of fibrinolytic agent and absence of T wave inversion in baseline electrocardiogram (ECG) are associated with achieving TIMI 3 flow after thrombolysis [3,4]. Hematological parameters of inflammation such as neutrophil-lymphocyte ratio (NLR) and mean platelet volume (MPV) were also found to be predictive of TIMI 3 flow after thrombolysis [5,6]. We studied the clinical, electrocardiographic and hematological parameters which were associated with finding angiographic TIMI 3 flow in patients presenting with STEMI who underwent thrombolysis with STK at our center. We also studied the one-month mortality of these patients.


Materials And Methods

We conducted a prospective observational study in the emergency and medical wards of Jawaharlal Institute of Postgraduate Medical Education and Research, a tertiary care hospital in Puducherry, Southern India. The study protocol was approved by the Institute Ethics Committee (JIP/IEC/2015/17/665). Between October 2015 and June 2017, we studied adult patients presenting within 12 hours of onset of chest pain to the emergency department who met the electrocardiographic (ECG) criteria for STEMI and underwent thrombolysis with STK. We excluded patients who underwent thrombolysis elsewhere and those who did not undergo CAG after thrombolysis. All patients received intravenous STK 1.5 million units administered over 60 minutes. An ethylenediaminetetraacetic acid (EDTA) sample for NLR and MPV was collected before administering STK. The samples were processed using an automated haematology analyser (Sysmex XT-1800i, Sysmex Corp., Kobe, Japan).

Following thrombolysis, ECGs were repeated at 90 and 120 minutes to observe ST segment recovery. Patients received the usual standard of care medications such as subcutaneous heparin, antiplatelet agents, statins, beta-blockers and ACE inhibitors. Timing of CAG after thrombolysis was decided by consultant cardiologists which varied depending on availability of cardiac catheterization laboratory. The TIMI flow grades are TIMI 0: absence of any antegrade flow beyond a coronary occlusion; TIMI 1: faint antegrade coronary flow beyond the occlusion, although filling of the distal coronary bed is incomplete; TIMI 2: delayed or sluggish antegrade flow with complete filling of the distal territory and TIMI 3: normal flow that fills the distal coronary bed completely [7]. Patients or their attendants were contacted telephonically one month later to determine patients’ survival status and to collect information on re-admissions or persistent symptoms.

Statistical analysis

To find out the factors associated with TIMI 3 flow we performed chi-square test for categorical variables and independent sample t-test or Wilcoxon rank-sum test for continuous variables. Those variables found to have a P-value of <0.1 were entered into a multivariable logistic regression model to find out factors independently associated with TIMI 3 flow. A two-sided P-value <0.05 was considered significant. All analyses were performed using the statistical software package Stata/IC 12.1 for Windows (StataCorp LP, College Station, Texas, USA).

Results

We included 201 patients. The STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) diagram (Figure 1) depicts the inclusion of participants in the study. The median (IQR) age of the patients was 55 (45-61) years, majority being males (168, 84%). Of the 201 patients, 180 (90%) were in Killip class 1, 16 (7.9%) in class 2, five (2.5) in class 3 while no patient was in class 4 at presentation. According to the baseline ECG, 111 (55.2%) had anteroseptal wall involvement and 90 (44.7%) had inferior wall involvement. At 90 minutes after thrombolysis, 162 (81%) had relief of chest pain and 131 (65%) had ST segment recovery of at least 50% in the ECG. At 120 minutes, further 26 patients reported relief of chest pain of whom 15 had resolution of ST segment elevation in the ECG. CAG was done within a median (IQR) of 4 (3-5) days after thrombolysis. TIMI 3 flow in the infarct-related artery was observed in 112 (56%) patients. The clinical, ECG and laboratory characteristics of patients with and without TIMI 3 flow is given in Table 1.
385 patients with STEMI presented to the emergency

- 113 thrombolysed elsewhere
- 26 underwent primary PCI
- 5 received alteplase

241 patients with STEMI thrombolysed with STK

- 18 had renal failure
- 13 patients expired
- 9 opted to seek care elsewhere

201 patients underwent CAG

198 patients followed up after 1 month

**FIGURE 1: The STROBE flow diagram**

STROBE: Strengthening the reporting of observational studies in epidemiology; STEMI: ST elevation myocardial infarction; PCI: Percutaneous coronary intervention; STK: Streptokinase; CAG: Coronary angiography.
Multivariable logistic regression analysis

We performed multivariable logistic regression analysis of variables which were significant in the univariate analysis. However, to avoid multi-collinearity, we omitted two variables; duration of chest pain and resolution of chest pain at 120 minutes. We also found that resolution of chest pain at 90 minutes was significantly associated with ST-segment recovery at 90 minutes (odds ratio 154.37, 95% CI: 20.42-1167; P < 0.001). Since the ECG parameter is more objective, we omitted chest pain relief at 90 minutes from the model. The final model had three variables of which ST-segment recovery of ≥50% at 90 minutes was found to be independently associated with TIMI 3 flow (Table 2). However, McFadden’s Pseudo R2 for this model was 0.089 which indicates that just less than 10% of variability of parameters is explained by the model [8].

---

### TABLE 1: Comparison of clinical, ECG and laboratory features in patients with TIMI 3 flow in CAG to those with TIMI 0, 1 or 2 flow

| Characteristics | Patients with TIMI 3 flow, N = 112 | Patients with TIMI 0, 1 or 2, N = 89 | P-value |
|-----------------|-----------------------------------|-------------------------------------|---------|
| Male sex, n (%) | 95 (85)                           | 73 (82)                             | 0.595   |
| Age (years), mean (±SD) | 53 (±11)                           | 55 (±11)                             | 0.129   |
| Hypertension    | 32 (29)                            | 27 (30)                             | 0.785   |
| Diabetes, n (%) | 34 (30)                            | 32 (36)                             | 0.401   |
| Smoking, n (%)  | 53 (47)                            | 41 (46)                             | 0.860   |
| Body mass index, kg/m², mean (±SD) | 24.4 (±2.1)                         | 24.5 (±2.1)                         | 0.775   |
| Systolic blood pressure at admission, mm of Hg, mean (±SD) | 126 (±21)                           | 121 (±23)                           | 0.105   |
| Diastolic blood pressure at admission, mm of Hg, mean (±SD) | 78.4 (±13)                          | 76.1 (±12)                          | 0.202   |
| Duration of chest pain (hours), mean (±SD) | 4.4 (±2.4)                          | 5.1 (±2.5)                          | 0.039   |
| Door to needle time in minutes, mean (±SD) | 38 (±22)                            | 38 (±23)                            | 0.946   |
| Total ischemic time in hours, mean (±SD) | 4.9 (±2.5)                          | 5.7 (±2.6)                          | 0.030   |
| Q waves in baseline ECG, n (%) | 70 (63)                             | 61 (69)                             | 0.372   |
| Inverted T waves in the ST elevated leads in baseline ECG, n (%) | 26 (23)                             | 36 (40)                             | 0.009   |
| Fragmented QRS complexes in baseline ECG, n (%) | 94 (84)                             | 68 (76)                             | 0.180   |
| Reduction of chest pain at 90 minutes, n (%) | 111 (99)                            | 61 (69)                             | <0.001  |
| ST-segment elevation recovery by ≥50% at 90 minutes, n (%) | 88 (79)                             | 43 (48)                             | <0.001  |
| Reduction of chest pain at 120 minutes, n (%) | 10 (9)                              | 16 (18)                             | 0.044   |
| ST-segment elevation recovery by ≥50% at 120 minutes, n (%) | 7 (6)                               | 8 (9)                               | 0.254   |
| Time gap between thrombolysis and CAG in days, median (IQR) | 4 (3-5)                             | 4 (3-5)                             | 0.425   |
| Neutrophil-lymphocyte ratio, median (IQR) | 4.6 (3.04-7.5)                       | 5.06 (3.5-7.2)                      | 0.239   |
| Mean platelet volume, femtolitre, mean (±SD) | 10 (±0.66)                          | 10 (±0.75)                          | 0.952   |

ECG: Electrocardiogram; TIMI: Thrombolysis in myocardial infarction; CAG: Coronary angiography; SD: Standard deviation; IQR: Interquartile range.

---

2021 Raghuram et al. Cureus 13(1): e12758. DOI 10.7759/cureus.12758
| Variables                                      | Adjusted odds ratio (95% CI)       | P-value |
|------------------------------------------------|-----------------------------------|---------|
| Total ischemic time                           | 0.96 (0.84-1.08)                  | 0.464   |
| Presence of inverted T waves in the ST elevated leads in the baseline ECG | 0.55 (0.29-1.06)                  | 0.075   |
| ST-segment elevation recovery by ≥50% at 90 minutes | 3.47 (1.84-6.53)                  | <0.001  |

**TABLE 2: Multivariable logistic regression analysis of factors associated with TIMI 3 flow in univariate analysis**

TIMI: Thrombolysis in myocardial infarction

---

**Mortality at one month**

Of 198 patients who were followed up for one month after discharge, 13 (6.5%) died. There were nine males and four females. Of the 13, three had undergone percutaneous intervention with stent placement after discharge. There was no statistically significant association with lower TIMI flow grades and mortality (OR [95% CI] 0.36 [0.11-1.2]); P = 0.084. However, our study was not adequately powered to show difference in mortality rates.

**Discussion**

We observed that in a population of 201 patients with STEMI treated with STK, ST-segment recovery of >50% at 90 minutes after thrombolysis independently predicts TIMI 3 flow. Although the lower total ischemic time, absence of T wave inversions in the baseline ECG and resolution of chest pain at 90 minutes were also significantly associated with patent IRA in univariate analysis, they were not significantly predictive in the multivariable model. We also observed a one-month mortality after discharge of 6.5%.

The proportion of patients with TIMI 3 flow (56%) as found in this study is similar to a full angiographic patency of 51% at 5-7 days which was observed in the STK with subcutaneous heparin arm of the GUSTO trial [9]. In GUSTO Angiographic Study, investigators studied the clinical predictors of early (90 minutes after thrombolysis) IRA patency [3]. They found that use of an accelerated tissue plasminogen activator (t-PA) regimen, anatomical localization of IRA (right coronary artery (RCA)/left circumflex artery (LCx) vs. left anterior descending (LAD)), body weight and smoking were predictive factors. However, we found no association of a particular IRA, BMI or smoking status with TIMI 3 flow. This could possibly happen because of the smaller sample size of our study. However, it is notable that other similarly large data sets like the pooled PAMI trial data found that particular localization of infarct vessel or current smoking did not predict TIMI3 flow [10].

A study similar to ours, which assessed predictors of coronary artery patency after thrombolysis with STK, was carried out by Gokhroo et al. in Rajasthan [11]. They included 100 patients who underwent CAG within 48 hours of thrombolysis with STK. They found that a patent IRA (defined as TIMI 2 or 3 flow) was present in 76% of patients. Of note, they observed that patency was more in patients presenting early (0-2 hours of chest pain onset). Indeed, the impact of total ischemic time on IRA patency has been observed in other studies also [12]. Although, we did not observe any significant association of total ischemic time with TIMI 3 flow, it is quite intuitive to minimize pre-hospital delays for achieving optimal efficacy of any reperfusion strategy.

We found that reduction in ST-segment elevation by >50% in the 90-minute ECG was associated with finding full angiographic patency, a finding which has been previously reported [13]. Studies show that ST-segment recovery also has prognostic significance in terms of predicting mortality and development of heart failure [14]. Conversely, patients without ST-segment recovery with persistent chest pain could benefit more by a pharmaco-invasive strategy. We found no significant association of NLR and MPV values and TIMI 3 flow. Some studies indicated that increased NLR and MPV could predict failed thrombolysis, no-reflow phenomenon in PCI and higher mortality [15,16]. However, these indices are non-specific markers of inflammation and have been observed to be elevated in non-cardiac diseases also [17,18].

The major limitation of our study is that we did not collect echocardiographic data to study the association of left ventricular function and IRA patency. Also, our follow-up period of one month was relatively short. The regression model evolved from our study data was modest in accounting for the variability in the outcome. However, this was not totally unexpected since multiple potential factors are known to influence TIMI flow grades [19,20]. Future studies from India evaluating the outcomes of thrombolysis with STK in STEMI should study incidence of major adverse cardiac events and mortality.
Conclusions
This study examined the clinical, electrocardiographic and hematological parameters associated with TIMI 3 flow after thrombolysis with STK in patients who presented to the emergency department with STEMI. We observed that among 201 patients with STEMI, around 60% had TIMI 3 flow following thrombolysis. In the univariate analysis, duration of chest pain, total ischemic time, inverted T waves in baseline ECG, reduction of chest pain at 90 and 120 minutes, and ST-segment recovery >50% in ECG at 90 minutes were found to be associated with TIMI 3 flow. However, age, sex and history of smoking were not found to have any significant association with TIMI 3 flow. NLR and MPV values were also not predictive of the same. Multivariable analysis found that ST-segment recovery >50% in ECG at 90 minutes was independently associated with TIMI 3 flow. The observed one-month mortality was 6.5% in patients who were followed up.

Additional Information

Disclosures

Human subjects: Consent was obtained by all participants in this study. Institute Ethics Committee (Human), JIPMER issued approval JIP/IEC/2015/17/665. The study protocol was approved by the Institute Ethics Committee (JIP/IEC/2015/17/665). Informed consent was taken from all study participants. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following:

Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Acknowledgements

We are thankful to Dr. Kadhiravan Tamilarasu, Additional Professor, Department of Medicine, JIPMER, Puducherry for critical inputs regarding statistical analysis.

References

1. Xavier D, Pais P, Devereux PJ, et al.: Treatment and outcomes of acute coronary syndromes in India (CREATE): a prospective analysis of registry data. Lancet. 2008, 371:1435-1442. 10.1016/S0140-6736(08)6025-6
2. Baliga RR, Bahl VK, Alexander T, Mullaasi A, Manga P, Dec GW, Nurula J: Management of STEMI in low- and middle-income countries. Glob Heart. 2014, 9:469-510. 10.1016/j.ghart.2014.11.001
3. Lundberg CF, Reiner JS, McCarthy WF, Coyne KS, Calif RM, Ross AM: Clinical predictors of early infarct-related artery patency following thrombolytic therapy: importance of body weight, smoking history, infarct-related artery and choice of thrombolytic regimens: the GUSTO-I experience. J Am Coll Cardiol. 1998, 32:641-647. 10.1016/S0735-1097(98)00278-2
4. Wong CK, Fench JK, Aylward PE, Frye MJ, Adgey AA, White HD: Usefulness of the presenting electrocardiogram in predicting successful reperfusion with Streptokinase in acute myocardial infarction. Am J Cardiol. 1999, 83:164-168. 10.1016/s0002-9149(98)00818-2
5. Erkol A, Onducu V, Turan B, et al.: Neutrophil to lymphocyte ratio in acute ST-segment elevation myocardial infarction. Am J Med Sci. 2014, 348:37-42. 10.1097/MAJ.0000000000000188
6. Varasateh-Ravan HR, Ali-Hazan-Al-Saegh S, Shokraneh S, Mozayan NR, Karimi-Bondarabadi AA: Relationship of admission mean platelet volume, platelet distribution width and white blood cells with ST resolution in patients with acute ST segment elevation myocardial infarction treated with streptokinase without history of previous cardiovascular surgery. Perspect Clin Res. 2015, 4:125-129. 10.4103/2229-3485.111792
7. The TIMI Study Group: The thrombolysis in myocardial infarction (TIMI) trial: phase I findings . N Engl J Med. 1985, 312:952-956. 10.1056/NEJM199504043292204
8. McFadden D: Conditional logit analysis of qualitative choice behavior . Frontiers in Econometrics. Zarembka P (ed): Academic Press, New York; 1974. 105-142.
9. GUSTO Angiographic Investigators: The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med. 1993, 329:1615-1622. 10.1056/NEJM199311253292204
10. Stone GW, Cox D, Garcia E, et al.: Normal flow (TIMI-3) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction: analysis from the primary angioplasty in myocardial infarction trials. Circulation. 2001, 104:636-641. 10.1161/hc3101.093701
11. Gokhroo RK, Gupta S, Bisht DS, Padmanabhan D: A study of coronary artery patency in relation to the index event in patients with myocardial infarction thrombolysed with streptokinase. Heart Asia. 2014, 6:55-58. 10.1186/heartasia-2014-010494
12. Denshtas AE, Anderson HV, McCarthy J, Smalling RW: Total ischemic time: the correct focus of attention for optimal ST-segment elevation myocardial infarction care. JACC Cardiovasc. Interv. 2011, 4:599-604. 10.1016/j.jcin.2011.02.012
13. de Lemos JA, Antman EM, Giugliano RP, et al.: ST-segment resolution and infarct-related artery patency and flow after thrombolytic therapy. Am J Cardiol. 2000, 85:299-304. 10.1016/s0002-9149(99)00736-5
14. de Lemos JA, Braunwald E: ST segment resolution as a tool for assessing the efficacy of reperfusion therapy . J Am Coll Cardiol. 2001, 38:1283-1294. 10.1016/s0735-1097(01)01550-9
15. Park JS, Seo KW, Choi BI, et al.: Importance of prognostic value of neutrophil to lymphocyte ratio in patients with ST-elevation myocardial infarction. Medicine (Baltimore). 2018, 97:13471. 10.1097/MD.0000000000013471

16. Wang Z, Ren L, Liu N, Peng J: Utility of hematological parameters in predicting no-reflow phenomenon after primary percutaneous coronary intervention in patients with st-segment elevation myocardial infarction. Clin Appl Thromb Hemost. 2018, 24:1177-1183. 10.1177/1076029618761005

17. Templeton AJ, McNamara MG, Šeruga B, et al.: Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014, 106:124. 10.1093/jnci/dju124

18. Kang WM, Zhu CZ, Yang XX, et al.: Application of the Onodera prognostic nutrition index and neutrophil-to-lymphocyte ratio in risk evaluation of postoperative complications in Crohn’s disease. Sci Rep. 2017, 7:8481. 10.1038/s41598-017-09265-3

19. Tan WA, Moliterno DJ: TIMI flow and surrogate end points: what you see is not always what you get. Am Heart J. 1998, 136:570-573. 10.1016/s0002-8703(98)70002-x

20. Zeymer U, Schröder R, Neuhaus KL: Patency, perfusion, and prognosis in acute myocardial infarction (Article in German). Herz. 1999, 24:421-429. 10.1007/BF03044428